In 2002, Frederic MASCHA took the opportunity of a first acquisition, Lysanxia® (prazepam), a psychiatric drug from Pfizer, to found a pharmaceutical company called LynaPharm, through a joint venture with the Italian pharmaceutical group, Sigma-Tau.
Later on, LynaPharm acquired the rights of Anafranil® (clomipramine), an antidepressant drug from Novartis, and Synedil® (sulpiride), for psychotic disorders from Astellas.
Frederic MASCHA and his holding company, Juvise, sold their LynaPharm shares to the Sigma-Tau group in 2008 to create Juvise Pharmaceuticals.
The story of Juvisé began in 2008. At that time, Frédéric Mascha, who already had extensive pharmaceutical and entrepreneurial experience, observed that in the United States, more and more companies were being created to secure the production, marketing and promotion of essential medicines, which some major pharma companies were gradually abandoning in favor of other therapeutic areas that were more strategic for them.
After the success of LynaPharm, he created Juvisé Pharmaceuticals, acquiring Lumirelax and Extovyl from Thera France. Since then, Juvisé Pharmaceuticals has continued to grow and develop year after year in new therapeutic areas, from rheumatology and neuropsychiatry to gastroenterology, cardiology and oncology, recording average annual sales growth of 33%.
creates Juvisé Pharmaceuticals